Ainos, Inc.

AIMD

US00902F3038

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1 ^USD	-3.85%		-5.66%	-51.22%

May. 15	Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment	MT
May. 15	Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market	CI

Amarillo Biosciences Inc. Announces Resignation of James A. Page as Director, Effective April 15, 2012

April 23, 2012 at 05:06 pm EDT

James A. Page, has resigned as a member of the board of directors of the Amarillo Biosciences Inc., effective April 15, 2012 for personal reasons.

Latest news about Ainos, Inc.

Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment	May. 15	MT
Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market	May. 15	CI
Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729	May. 13	MT
Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	Mar. 19	CI
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer	Mar. 15	CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	Mar. 11	MT
Top Premarket Decliners	Mar. 11	MT
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Top Premarket Gainers	Mar. 08	MT
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial	Feb. 05	MT
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	Feb. 05	CI
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	Jan. 12	CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05	MT
Ainos Regains Compliance With Nasdaq Listing Rule	Jan. 02	MT
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	Dec. 26	CI
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	Dec. 22	CI
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	Nov. 21	MT
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	Nov. 21	CI
Earnings Flash (AIMD) AINOS Reports Q3 Revenue $24,489	Nov. 09	MT
Ainos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Ainos, Inc. Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on Veldona	Nov. 06	CI
Ainos to Issue Preliminary $3 Million Portion of Expected $10 Million Notes Placement	23-09-25	MT
Ainos Says Candidate Treatment for HIV Oral Warts Gets Orphan Drug Designation	23-09-18	MT
Ainos, Inc. Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan	23-09-05	CI
Earnings Flash (AIMD) AINOS Reports Q2 Revenue $28,555	23-08-11	MT

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AINOS, INC.	-51.22%	6.39M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs

Ainos, Inc.

Equities

AIMD

US00902F3038

Biotechnology & Medical Research

Amarillo Biosciences Inc. Announces Resignation of James A. Page as Director, Effective April 15, 2012

Latest news about Ainos, Inc.

Chart Ainos, Inc.

Company Profile

Income Statement Evolution

Sector Bio Therapeutic Drugs